A Novel Approach to Block HIV-1 Coreceptor CXCR4 in Non-toxic Manner

Molecular Biotechnology

Volumn 56, Issue 10, 2014, Pages 890-902

  Liu, Ye ^a   Zhou, Jieqiong ^a   Pan, Ji An ^a,c   Mabiala, Prudence ^a   Guo, Deyin ^a,b  

^a WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

CXCR4; HIV 1; Lentiviral vector; shRNA

Indexed keywords

VIRUSES;

CHEMOKINE RECEPTOR CXCR4; CXCR4; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS TYPE-1; LENTIVIRAL VECTOR; SHRNA; TARGETED THERAPEUTICS; UNIVERSAL APPLICATION;

DISEASES;

CHEMOKINE RECEPTOR CXCR4; MESSENGER RNA; MUTANT PROTEIN; SMALL INTERFERING RNA;

AMINO ACID SEQUENCE; BIOTECHNOLOGY; CHEMISTRY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEK293 CELL LINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRINAE; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROCEDURES; VIRUS REPLICATION;

AMINO ACID SEQUENCE; BASE SEQUENCE; BIOTECHNOLOGY; GENETIC VECTORS; HEK293 CELLS; HIV-1; HUMANS; LENTIVIRUS; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; MUTATION; RECEPTORS, CXCR4; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

EID: 84920259583     PISSN: 10736085     EISSN: 15590305     Source Type: Journal    
DOI: 10.1007/s12033-014-9768-7     Document Type: Article

References (46)

1. Gorry, P. R., & Ancuta, P. (2011). Coreceptors and HIV-1 pathogenesis. Current HIV/AIDS Reports,8(1), 45–53.
2. Alkhatib, G. (2009). The biology of CCR5 and CXCR4. Current Opinion in HIV and AIDS,4(2), 96–103.
3. Doranz, B. J., et al. (2001). Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Research and Human Retroviruses,17(6), 475–486.
4. Murakami, T., et al. (1997). A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. Journal of Experimental Medicine,186(8), 1389–1393.
5. Tamamura, H., et al. (1998). A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochemical and Biophysical Research Communications,253(3), 877–882.
6. Hendrix, C. W., et al. (2000). Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrobial Agents and Chemotherapy,44(6), 1667–1673.
7. Hendrix, C. W., et al. (2004). Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes,37(2), 1253–1262.
8. Stone, N. D., et al. (2007). Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrobial Agents and Chemotherapy,51(7), 2351–2358.
9. Jahnichen, S., et al. (2010). CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proceedings of the National Academy of Science USA,107(47), 20565–20570.
10. Anderson, J., et al. (2003). Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Research and Human Retroviruses,19(8), 699–706.
11. Zhou, N., et al. (2004). Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Gene Therapy,11(23), 1703–1712.
12. Schols, D. (2004). HIV co-receptors as targets for antiviral therapy. Current Topics in Medicinal Chemistry,4(9), 883–893.
13. Gonzalo, J. A., et al. (2000). Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1 alpha in the inflammatory component of allergic airway disease. Journal of Immunology,165(1), 499–508.
14. Ratajczak, M. Z., et al. (2006). The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia,20(11), 1915–1924.
15. Bleul, C. C., et al. (1996). The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature,382(6594), 829–833.
16. Oberlin, E., et al. (1996). The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature,382(6594), 833–835.
17. Tian, S., et al. (2005). Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1alpha on CXCR4 transmembrane helical domains. Journal of Virology,79(20), 12667–12673.
18. Rubinson, D. A., et al. (2003). A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nature Genetics,33(3), 401–406.
19. Miyagishi, M., & Taira, K. (2002). U6 promoter-driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nature Biotechnology,20(5), 497–500.
20. Surabhi, R. M., & Gaynor, R. B. (2002). RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication. Journal of Virology,76(24), 12963–12973.
21. Morner, A., et al. (1999). Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. Journal of Virology,73(3), 2343–2349.
22. Robbins, M. A., et al. (2006). Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nature Biotechnology,24(5), 566–571.
23. Anderson, J., & Akkina, R. (2005). HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Research and Therapy,2(1), 1.
24. Szymczak, A. L., et al. (2004). Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. Nature Biotechnology,22(5), 589–594.
25. Hu, T., et al. (2009). Generation of a stable mammalian cell line for simultaneous expression of multiple genes by using 2A peptide-based lentiviral vector. Biotechnology Letters,31(3), 353–359.
26. Doronina, V. A., et al. (2008). Dissection of a co-translational nascent chain separation event. Biochemical Society Transactions,36(Pt 4), 712–716.
27. Schwarz, D. S., et al. (2006). Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genetics,2(9), e140.
28. Judge, A. D., et al. (2005). Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nature Biotechnology,23(4), 457–462.
29. Eekels, J. J., et al. (2012). A competitive cell growth assay for the detection of subtle effects of gene transduction on cell proliferation. Gene Therapy,19(11), 1058–1064.
30. Muller, A., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature,410(6824), 50–56.
31. Burger, J. A., Burger, M., & Kipps, T. J. (1999). Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood,94(11), 3658–3667.
32. Hutter, G., et al. (2009). Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. New England Journal of Medicine,360(7), 692–698.
33. Allers, K., et al. (2011). Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood,117(10), 2791–2799.
34. van Lunzen, J., et al. (2007). Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Molecular Therapy,15(5), 1024–1033.
35. Vets, S., et al. (2012). Lens epithelium-derived growth factor/p75 qualifies as a target for HIV gene therapy in the NSG mouse model. Molecular Therapy,20(5), 908–917.
36. Kohn, D. B., et al. (1999). A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood,94(1), 368–371.
37. Mitsuyasu, R. T., et al. (2009). Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nature Medicine,15(3), 285–292.
38. ter Brake, O., et al. (2008). Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Molecular Therapy,16(3), 557–564.
39. Eekels, J. J., et al. (2011). Long-term inhibition of HIV-1 replication with RNA interference against cellular co-factors. Antiviral Research,89(1), 43–53.
40. Perez, E. E., et al. (2008). Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nature Biotechnology,26(7), 808–816.
41. Wilen, C. B., et al. (2011). Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathogens,7(4), e1002020.
42. DiGiusto, D. L., et al. (2010). RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Science Translational Medicine,2(36), 36ra43.
43. Walker, J. E., et al. (2012). Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. Journal of Virology,86(10), 5719–5729.
44. Kiem, H. P., et al. (2010). Foamy combinatorial anti-HIV vectors with MGMTP140 K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo. Gene Therapy,17(1), 37–49.
45. Friedrich, B. M., et al. (2011). Host factors mediating HIV-1 replication. Virus Research,161(2), 101–114.
46. Burnett, J. C., Zaia, J. A., & Rossi, J. J. (2012). Creating genetic resistance to HIV. Current Opinion in Immunology,24(5), 625–632.